ClinicalTrials.gg
CompletedNCT00519285VENICEUpdated Jul 22, 2016Results posted

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

A Phase 3 interventional study of Aflibercept and Placebo (for aflibercept) in Prostatic Neoplasms and Neoplasm Metastasis, sponsored by Sanofi. Completed at 31 sites in 31 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-22.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,224
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 34 studies in Prostatic Neoplasms by Sanofi — none open to participants now, none under way, none of them phase 3. Prostatic Neoplasms · Sanofi.

Enrollment
Largest of 31
1,224 · median 54
Started
2007
with 3 others
Phase 3
10 of 34
none open now
Registered
14th of 34
by date

Among the 34 studies in Prostatic Neoplasms by Sanofi, this one has the largest enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2007, is one of 10 in phase 3, and was the 14th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

None of the 34 studies in Prostatic Neoplasms by Sanofi is open now. The open studies under Prostatic Neoplasms, anywhere →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies in Prostatic Neoplasms by Sanofi as a file.
02

Study summary

Primary objective was to demonstrate overall survival improvement with aflibercept compared to placebo in patients receiving docetaxel / prednisone for metastatic androgen-independent prostate cancer (MAIPC).

The secondary objectives were:

  • To assess the efficacy of aflibercept compared to placebo on other parameters such prostate-specific antigen (PSA) level, cancer related pain, progression free survival (PFS), tumor-based and skeletal events and health-related quality of life (HRQL);
  • To assess the overall safety in both treatment arms;
  • To determine the pharmacokinetics of intravenous (IV) aflibercept in this population;
  • to determine immunogenicity of IV aflibercept.
Read the detailed description

The study consisted in 3-week treatment cycles until progressive disease, unacceptable toxicity, or participant's refusal of further study treatment. After disease progression, participants were to be followed every 3 months until death or the study cutoff date, whichever came first.

The study cut-off date was event-driven and was defined as the date when 873 deaths had occurred.

03

Conditions studied

  • Prostatic Neoplasms
  • Neoplasm Metastasis

Keywords

  • metastatic
  • prostate
  • cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - or cytologically-confirmed prostate adenocarcinoma;
  • disease;
  • Progressive disease while receiving hormonal therapy or after surgical castration;
  • Effective castration.

Exclusion criteria

Exclusion Criteria:

  • Prior cytotoxic chemotherapy for prostate cancer, except estramustine and except /neoadjuvant treatment completed >3 years ago;
  • Prior treatment with Vascular Endothelial Growth Factor (VEGF) inhibitors or VEGF receptor inhibitors;
  • (ECOG) performance status >2.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,224 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo added to standard chemotherapy with docetaxel plus prednisone or prednisolone

    Drug: Placebo (for aflibercept) · Drug: Docetaxel · Drug: Prednisone or Prednisolone

  • Experimental
    Aflibercept

    Aflibercept added to standard chemotherapy with docetaxel plus prednisone or prednisolone

    Drug: Aflibercept · Drug: Docetaxel · Drug: Prednisone or Prednisolone

Interventions

  • 25 mg/ml solution 6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle

    Also known as: AVE0005, ZALTRAP®)

  • DrugPlacebo (for aflibercept)

    Sterile aqueous buffered solution identical to aflibercept 1-hour IV on Day 1 of each 3-Week cycle

  • Marketed formulation 75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)

    Also known as: Taxotere®

  • DrugPrednisone or Prednisolone

    Drug pages: Prednisone · Prednisolone

    Marketed formulation 5 mg twice daily PO from day 1 continuously

06

What researchers measure

Primary outcomes

  1. Overall Survival Time

    Overall survival (OS) time was measured as the time from date of randomization to the date of death due to any cause. The median OS time and its 95.6% confidence interval were estimated using the Kaplan-Meier method. In the absence of confirmation of death, the participant was censored at the last date he/she was known to be alive or the study cut-off date (when 873 deaths have occurred), whichever was earlier.

    Time frame: From randomization up to the cut-off date (median follow-up of 35.4 months)

Secondary outcomes

  1. Prostate Specific Antigen Response Rate

    Prostate specific antigen (PSA) response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed at least 3 weeks later. Increases of any magnitude during the first 12 weeks were ignored in determining PSA response.

    Time frame: Before randomization (baseline) then every 3 weeks up to PSA progression (≥25% increase) or the cut-off date, whichever occurred first

  2. Time to Skeletal Related Events

    Skeletal Related Events (SRE) included pathological fractures and/or spinal cord compression, need for bone irradiation, including radioisotopes or bone surgery, change in antineoplastic therapy to treat bone pain. Time to SRE was defined as the time from the date of randomization to the date of occurence of the first event defining a SRE or death due to any cause, whichever occurred first. The median time to SRE and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of SRE, the participant was censored at the last date he/she was known to be alive or the study cut-off date, whichever was earlier.

    Time frame: From randomization up to the cut-off date (median follow-up of 35.4 months)

  3. Progression Free Survival Time

    Disease progression was defined as a composite of: Radiological tumor progression (≥20% increase in target lesions, or appearance of at least 2 new bone lesions); PSA progression (≥25% increase in PSA level confirmed 3 weeks later); Pain progression (increase in pain intensity or in analgesic consumption for cancer related pain confirmed 3 weeks later); Radiotherapy for cancer related symptoms; Occurence of Skeletal related events (SRE). Progression Free survival (PFS) time was measured as the time from the date of randomization up to the date of occurrence of the first event defining a disease progression or death due to any cause, whichever occurred first. The median PFS time and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of disease progression, the participant was censored at the the date of last assessment without evidence of progression or the study cut-off date, whichever was earlier.

    Time frame: From randomization up to the cut-off date (median follow-up of 35.4 months)

  4. Tumor Response Rate in Participants With Measurable Disease

    Tumor response was defined as either a Complete Response (disappearance of all target lesions) or a Partial Response (≥30% decrease from baseline in target lesions) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST)version 1.0.

    Time frame: Before randomization (baseline) then every 3 months up to tumor progression (≥25% increase) or the cut-off date, whichever occurred first

  5. Prostate Specific Antigen Progression-free Survival Time

    Prostate specific antigen (PSA) progression was defined as ≥25% increase in PSA level confirmed 3 weeks later, above the nadir in participants who had achieved a PSA response, or above the baseline in participants who hadn't achieved a PSA response. PSA progression-free survival (PFS) time was defined as the time from the date of randomization up to the date of the first documented PSA progression or death due to any cause, whichever occurred first. The median PSA-PFS time and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of PSA progression or death, the participant was censored at the the date of last assessment without evidence of progression or the study cut-off date, whichever was earlier.

    Time frame: From randomization up to the cut-off date (median follow-up of 35.4 months)

  6. Pain Progression-free Survival Time

    Pain progression was defined as either ≥1-point increase in Present Pain Intensity (PPI) score or ≥25% increase in Analgesics Score (AS) confirmed at least 3 weeks later, or requirement for palliative radiotherapy. PPI scale is a self-report 0-5 scale to assess pain intensity - a score 0 reflects no pain, a score 5 reflects excruciating pain. AS is a scoring method to assess analgesics consumption. Each analgesic is scored 1 or 4 depending on the analgesic type and dose. AS is the sum of the analgesic scores. Pain progression-free survival (PFS) time was measured as the time from the date of randomization up to the date of first pain progression or death due to any cause, whichever occurred first. The median pain-PFS and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of event, the participant was censored at the the date of last assessment without evidence of pain progression or the study cut-off date, whichever was earlier.

    Time frame: From randomization up to the cut-off date (median follow-up of 35.4 months)

  7. Pain Response Rate

    Pain response was defined as either a ≥2-point decrease from baseline in Present Pain Intensity (PPI) score without increase in Analgesics Score (AS), or a ≥50% decrease from baseline in AS without increase in the PPI score confirmed at least 3 weeks later. Increases in PPI or AS during the first 12 weeks were ignored in determining pain response.

    Time frame: Before randomization (baseline) then every 3 weeks up to pain progression or the cut-off date, whichever occurred first

  8. Change From Baseline in Functional Assessment of Cancer Therapy-Prostate Total Score as a Measure of Health Related Quality of Life

    Functional Assessment of Cancer Therapy-Prostate (FACT-P) is a 39-item participant questionnaire that measures the concerns of patients with prostate cancer. It consists of 5 subscales assessing physical well-being, social/family well-being, emotional well-being, functional well-being, and prostate-specific concerns. FACT-P total score is the sum of the 5 subscores. It ranges from 0 to 156 with higher score indicating better quality of life.

    Time frame: Before randomization (baseline) then every 3 weeks until disease progression or administration of further antitumor therapy, whichever came first

  9. Number of Participants With Adverse Events as a Measure of Safety

    Adverse Events (AE) are any unfavorable and unintended sign, symptom, syndrome or illness observed by the investigator or reported by the participant during the study. AE were collected at regular intervals throughout the study then graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v.3.0).

    Time frame: From first dose of study treatment (aflibercept/placebo or docetaxel whichever came first) to last dose of study treatment (aflibercept/placebo or docetaxel whichever came last) + 30 days

  10. Number of Participants With Positive Anti-aflibercept Antibody Levels as a Measure of Immunogenicity of Aflibercept

    Serum for detection of anti-drug antibodies (ADA) was collected in patients treated in selected centers only. Samples were analyzed using a titer-based, bridging immunoassay developed and validated to detect ADAs in human serum. Samples with positive antibody levels were further analyzed using a validated, non-quantitative ligand binding assay to detect neutralizing antibodies Ab). A participant was considered to have positive antibody levels if antibodies were detected above the quantification limits.

    Time frame: Pre-dose of cycle 1 (baseline), pre-dose of each every other cycle, then 30 and 90 days after the last administration of the study drug

07

Results

Posted Oct 10, 2013
Limitations and caveats
Pain response initially defined as a key secondary endpoint together with PSA response, time to occurence of SRE and PFS was finally considered as an exploratory endpoint in final statistical analysis plan.

Participant flow

Between August 2007 and February 2010, a total of 1548 patients gave informed consent for this study.

Participant flow — Overall Study
MilestonePlaceboAflibercept
Started612612
Treated604605
Still treated at cut-off date12
Completed00
Not completed612612
Withdrew: Adverse event127266
Withdrew: Disease progression334186
Withdrew: Physician decision7547
Withdrew: Participant's request5384
Withdrew: Consent withdrawn45
Withdrew: Poor compliance to protocol57
Withdrew: Reason unspecified58
Withdrew: Not treated87
Withdrew: Treatment ongoing12

Outcome measures

PrimaryOverall Survival Time

Overall survival (OS) time was measured as the time from date of randomization to the date of death due to any cause. The median OS time and its 95.6% confidence interval were estimated using the Kaplan-Meier method. In the absence of confirmation of death, the participant was censored at the last date he/she was known to be alive or the study cut-off date (when 873 deaths have occurred), whichever was earlier.

Time frame:
From randomization up to the cut-off date (median follow-up of 35.4 months)
Reported as:
Median · months
Overall Survival Time
monthsPlaceboAflibercept
Overall Survival Time21.22 (19.614 to 23.754)22.14 (20.304 to 24.082)
Statistical analysis
  • Placebo vs Aflibercept · Log Rank · p = 0.3802 (A priori threshold for statistical significance was set to 0.044 using the O'Brien-Fleming alpha spending function to account for two interim analyses.) · Hazard ratio (hr): 0.942 · 95.6% CI 0.822 to 1.08Hazard ratio (HR) aflibercept versus placebo estimated from a Cox proportional hazard model stratified on ECOG Performance Status
SecondaryProstate Specific Antigen Response Rate

Prostate specific antigen (PSA) response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed at least 3 weeks later. Increases of any magnitude during the first 12 weeks were ignored in determining PSA response.

Time frame:
Before randomization (baseline) then every 3 weeks up to PSA progression (≥25% increase) or the cut-off date, whichever occurred first
Reported as:
Number · percentage of participants
Prostate Specific Antigen Response Rate
percentage of participantsPlaceboAflibercept
Prostate Specific Antigen Response Rate63.5 (59.5 to 67.5)68.6 (64.7 to 72.4)
SecondaryTime to Skeletal Related Events

Skeletal Related Events (SRE) included pathological fractures and/or spinal cord compression, need for bone irradiation, including radioisotopes or bone surgery, change in antineoplastic therapy to treat bone pain. Time to SRE was defined as the time from the date of randomization to the date of occurence of the first event defining a SRE or death due to any cause, whichever occurred first. The median time to SRE and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of SRE, the participant was censored at the last date he/she was known to be alive or the study cut-off date, whichever was earlier.

Time frame:
From randomization up to the cut-off date (median follow-up of 35.4 months)
Reported as:
Median · months
Time to Skeletal Related Events
monthsPlaceboAflibercept
Time to Skeletal Related Events14.98 (13.733 to 16.427)15.31 (14.127 to 16.657)
SecondaryProgression Free Survival Time

Disease progression was defined as a composite of: Radiological tumor progression (≥20% increase in target lesions, or appearance of at least 2 new bone lesions); PSA progression (≥25% increase in PSA level confirmed 3 weeks later); Pain progression (increase in pain intensity or in analgesic consumption for cancer related pain confirmed 3 weeks later); Radiotherapy for cancer related symptoms; Occurence of Skeletal related events (SRE). Progression Free survival (PFS) time was measured as the time from the date of randomization up to the date of occurrence of the first event defining a disease progression or death due to any cause, whichever occurred first. The median PFS time and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of disease progression, the participant was censored at the the date of last assessment without evidence of progression or the study cut-off date, whichever was earlier.

Time frame:
From randomization up to the cut-off date (median follow-up of 35.4 months)
Reported as:
Median · months
Progression Free Survival Time
monthsPlaceboAflibercept
Progression Free Survival Time6.24 (5.585 to 6.899)6.90 (6.209 to 7.359)
SecondaryTumor Response Rate in Participants With Measurable Disease

Tumor response was defined as either a Complete Response (disappearance of all target lesions) or a Partial Response (≥30% decrease from baseline in target lesions) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST)version 1.0.

Time frame:
Before randomization (baseline) then every 3 months up to tumor progression (≥25% increase) or the cut-off date, whichever occurred first
Reported as:
Number · percentage of participants
Tumor Response Rate in Participants With Measurable Disease
percentage of participantsPlaceboAflibercept
Tumor Response Rate in Participants With Measurable Disease28.1 (23.2 to 33.1)38.7 (33.4 to 44.0)
SecondaryProstate Specific Antigen Progression-free Survival Time

Prostate specific antigen (PSA) progression was defined as ≥25% increase in PSA level confirmed 3 weeks later, above the nadir in participants who had achieved a PSA response, or above the baseline in participants who hadn't achieved a PSA response. PSA progression-free survival (PFS) time was defined as the time from the date of randomization up to the date of the first documented PSA progression or death due to any cause, whichever occurred first. The median PSA-PFS time and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of PSA progression or death, the participant was censored at the the date of last assessment without evidence of progression or the study cut-off date, whichever was earlier.

Time frame:
From randomization up to the cut-off date (median follow-up of 35.4 months)
Reported as:
Median · months
Prostate Specific Antigen Progression-free Survival Time
monthsPlaceboAflibercept
Prostate Specific Antigen Progression-free Survival Time8.11 (7.622 to 8.575)8.25 (7.819 to 8.772)
SecondaryPain Progression-free Survival Time

Pain progression was defined as either ≥1-point increase in Present Pain Intensity (PPI) score or ≥25% increase in Analgesics Score (AS) confirmed at least 3 weeks later, or requirement for palliative radiotherapy. PPI scale is a self-report 0-5 scale to assess pain intensity - a score 0 reflects no pain, a score 5 reflects excruciating pain. AS is a scoring method to assess analgesics consumption. Each analgesic is scored 1 or 4 depending on the analgesic type and dose. AS is the sum of the analgesic scores. Pain progression-free survival (PFS) time was measured as the time from the date of randomization up to the date of first pain progression or death due to any cause, whichever occurred first. The median pain-PFS and its 95% confidence interval were estimated using the Kaplan-Meier method. In the absence of event, the participant was censored at the the date of last assessment without evidence of pain progression or the study cut-off date, whichever was earlier.

Time frame:
From randomization up to the cut-off date (median follow-up of 35.4 months)
Reported as:
Median · months
Pain Progression-free Survival Time
monthsPlaceboAflibercept
Pain Progression-free Survival Time9.72 (8.509 to 11.499)9.20 (8.181 to 10.448)
SecondaryPain Response Rate

Pain response was defined as either a ≥2-point decrease from baseline in Present Pain Intensity (PPI) score without increase in Analgesics Score (AS), or a ≥50% decrease from baseline in AS without increase in the PPI score confirmed at least 3 weeks later. Increases in PPI or AS during the first 12 weeks were ignored in determining pain response.

Time frame:
Before randomization (baseline) then every 3 weeks up to pain progression or the cut-off date, whichever occurred first
Reported as:
Number · percentage of participants
Pain Response Rate
percentage of participantsPlaceboAflibercept
Pain Response Rate46.3 (34.3 to 58.2)35.8 (24.3 to 47.3)
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Prostate Total Score as a Measure of Health Related Quality of Life

Functional Assessment of Cancer Therapy-Prostate (FACT-P) is a 39-item participant questionnaire that measures the concerns of patients with prostate cancer. It consists of 5 subscales assessing physical well-being, social/family well-being, emotional well-being, functional well-being, and prostate-specific concerns. FACT-P total score is the sum of the 5 subscores. It ranges from 0 to 156 with higher score indicating better quality of life.

Time frame:
Before randomization (baseline) then every 3 weeks until disease progression or administration of further antitumor therapy, whichever came first
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Prostate Total Score as a Measure of Health Related Quality of Life
units on a scalePlaceboAflibercept
Change from baseline at cycle 1 (n =493, 461)5.08 ± 12.731.30 ± 15.70
Change from baseline at cycle 2 (n =467, 437)6.22 ± 14.50-0.03 ± 17.99
Change from baseline at cycle 6 (n =293, 224)5.50 ± 16.38-1.00 ± 16.85
Change from baseline at cycle 10 (n =158, 117)6.61 ± 16.35-1.60 ± 15.41
SecondaryNumber of Participants With Adverse Events as a Measure of Safety

Adverse Events (AE) are any unfavorable and unintended sign, symptom, syndrome or illness observed by the investigator or reported by the participant during the study. AE were collected at regular intervals throughout the study then graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v.3.0).

Time frame:
From first dose of study treatment (aflibercept/placebo or docetaxel whichever came first) to last dose of study treatment (aflibercept/placebo or docetaxel whichever came last) + 30 days
Reported as:
Number · participants
Number of Participants With Adverse Events as a Measure of Safety
participantsPlaceboAflibercept
Any Adverse Event585607
- Grade 3-4 AE290470
- Serious AE184331
- AE leading to death2346
--- Related AE leading to death819
- AE leading to permanent discontinuation125268
- AE leading to premature discontinuation73116
SecondaryNumber of Participants With Positive Anti-aflibercept Antibody Levels as a Measure of Immunogenicity of Aflibercept

Serum for detection of anti-drug antibodies (ADA) was collected in patients treated in selected centers only. Samples were analyzed using a titer-based, bridging immunoassay developed and validated to detect ADAs in human serum. Samples with positive antibody levels were further analyzed using a validated, non-quantitative ligand binding assay to detect neutralizing antibodies Ab). A participant was considered to have positive antibody levels if antibodies were detected above the quantification limits.

Time frame:
Pre-dose of cycle 1 (baseline), pre-dose of each every other cycle, then 30 and 90 days after the last administration of the study drug
Reported as:
Number · participants
Number of Participants With Positive Anti-aflibercept Antibody Levels as a Measure of Immunogenicity of Aflibercept
participantsPlaceboAflibercept
At baseline02
At any time post-baseline49
- Neutralizing Ab02
- Not neutralizing Ab25
- Neutralizing potential not evaluated22

Adverse events

Collected over Adverse Events (AE) were collected from signature of the informed consent form up to the last visit in the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—184/598 (30.8%)551/598 (92.1%)
Aflibercept—331/611 (54.2%)573/611 (93.8%)
Most frequent serious events
Showing 10 of 275
Most frequent serious events
EventPlaceboAflibercept
Febrile neutropeniaBlood and lymphatic system disorders21/59848/611
NeutropeniaBlood and lymphatic system disorders8/59830/611
Neutropenic infectionInfections and infestations12/59822/611
PneumoniaInfections and infestations11/59821/611
EpistaxisRespiratory, thoracic and mediastinal disorders1/59820/611
DehydrationMetabolism and nutrition disorders2/59819/611
Pulmonary embolismRespiratory, thoracic and mediastinal disorders17/59813/611
DiarrhoeaGastrointestinal disorders11/59817/611
StomatitisGastrointestinal disorders1/59814/611
Anal abscessInfections and infestations0/59813/611
Most frequent other events
Showing 10 of 44
Most frequent other events
EventPlaceboAflibercept
StomatitisGastrointestinal disorders123/598340/611
AlopeciaSkin and subcutaneous tissue disorders268/598224/611
DiarrhoeaGastrointestinal disorders209/598268/611
FatigueGeneral disorders241/598243/611
DysphoniaRespiratory, thoracic and mediastinal disorders36/598230/611
HypertensionVascular disorders66/598207/611
Weight decreasedInvestigations51/598201/611
EpistaxisRespiratory, thoracic and mediastinal disorders55/598199/611
Decreased appetiteMetabolism and nutrition disorders110/598190/611
NauseaGastrointestinal disorders166/598165/611

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboAfliberceptTotal
Mean67.6 ± 8.067.9 ± 7.867.8 ± 7.9
Age, Customized
Age, Customized(participants)PlaceboAfliberceptTotal
<65 years225195420
65-74 years259283542
≥75 years128134262
Sex/Gender, Customized
Sex/Gender, Customized(participants)PlaceboAfliberceptTotal
Male6126121224
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboAfliberceptTotal
Caucasian/White5525601112
Black171532
Asian/Oriental363268
Other7512
Region of Enrollment
Region of Enrollment(Participants)PlaceboAfliberceptTotal
Western Europe219227446
Eastern Europe131132263
North America8195176
South America8871159
Other region9387180
Body Surface Area (BSA)
Body Surface Area (BSA)(m²)PlaceboAfliberceptTotal
Mean2.0 ± 0.22.0 ± 0.22.0 ± 0.2
Eastern Co-operative Group (ECOG) performance status
Eastern Co-operative Group (ECOG) performance status(participants)PlaceboAfliberceptTotal
ECOG 0285283568
ECOG 1299303602
ECOG 2282654
08

Study locations

31 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Buenos Aires, Argentina
  • Sanofi-Aventis Administrative Office
    Macquarie Park, Australia
  • Sanofi-Aventis Administrative Office
    Diegem, Belgium
  • Sanofi-Aventis Administrative Office
    Sao Paulo, Brazil
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Providencia Santiago, Chile
  • Sanofi-Aventis Administrative Office
    City of Zagreb, Croatia
  • Sanofi-Aventis Administrative Office
    Praha, Czech Republic
  • Sanofi-Aventis Administrative Office
    Horsholm, Denmark
  • Sanofi-Aventis Administrative Office
    Tallinn, Estonia
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Frankfurt, Germany
  • Sanofi-Aventis Administrative Office
    Hong Kong, Hong Kong
  • Sanofi-Aventis Administrative Office
    Budapest, Hungary
  • Sanofi-Aventis Administrative Office
    Natanya, Israel
  • Sanofi-Aventis Administrative Office
    Milan, Italy
  • Sanofi-Aventis Administrative Office
    Seoul, Korea, Republic of
  • Sanofi-Aventis Administrative Office
    Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Warsaw, Poland
  • Sanofi-Aventis Administrative Office
    Porto Salvo, Portugal
  • Sanofi-Aventis Administrative Office
    Moscow, Russian Federation
  • Sanofi-Aventis Administrative Office
    Singapore, Singapore
  • Sanofi-Aventis Administrative Office
    Gauteng, South Africa
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Bromma, Sweden
  • Sanofi-Aventis Administrative Office
    Geneva, Switzerland
  • Sanofi-Aventis Administrative Office
    Taipei, Taiwan
  • Sanofi-Aventis Administrative Office
    Istanbul, Turkey
  • Sanofi-Aventis Administrative Office
    Kiev, Ukraine
  • Sanofi-Aventis Administrative Office
    Guildford Surrey, United Kingdom
09

References and documents

Publications

  • Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Flechon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Aren O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M; VENICE investigators. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013 Jul;14(8):760-8. doi: 10.1016/S1470-2045(13)70184-0. Epub 2013 Jun 4. PubMed 23742877 ↗
  • van Soest RJ, Templeton AJ, Vera-Badillo FE, Mercier F, Sonpavde G, Amir E, Tombal B, Rosenthal M, Eisenberger MA, Tannock IF, de Wit R. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol. 2015 Apr;26(4):743-749. doi: 10.1093/annonc/mdu569. Epub 2014 Dec 15. PubMed 25515657 ↗
  • de Liano AG, Reig O, Mellado B, Martin C, Rull EU, Maroto JP. Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer. Br J Cancer. 2014 Apr 29;110(9):2201-8. doi: 10.1038/bjc.2014.189. Epub 2014 Apr 10. PubMed 24722180 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2007
First posted
Aug 22, 2007
Start
Aug 2007
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results first posted
Oct 10, 2013
Last update
Jul 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00519285
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 22, 2007
Start date
Aug 2007
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
Oct 10, 2013
Last update
Jul 22, 2016

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion